智通财经APP讯,和铂医药-B(02142)发布公告,公司的合作伙伴Windward Bio AG(Windward Bio)已在HBM9378/WIN378(亦称SKB378,一款全人源超长效靶向胸腺基质淋巴细胞生成素(TSLP)抗体)治疗慢性阻塞性肺疾病(COPD)的II期 SIRIUS研究中完成首批患者给药。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.